DAYTON CLINICAL ONCOLOGY PROGRAM

代顿临床肿瘤学项目

• 批准号: 6512440
• 负责人: Howard M Gross
• 金额: $ 65.04万
• 依托单位: DAYTON CLINICAL ONCOLOGY PROGRAM
• 依托单位国家: 美国
• 财政年份: 1983
• 资助国家: 美国
• 起止时间: 1983-09-15 至 2004-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6512440
• 关键词: behavioral /social science research tag; cancer information system; cancer prevention; cancer registry /resource; cancer rehabilitation /care; clinical research; clinical trials; community health services; continuing education; cooperative study; data management; early diagnosis; health services research tag; human subject; human therapy evaluation; medical outreach /case finding; medical rehabilitation related tag; neoplasm /cancer diagnosis; neoplasm /cancer education; neoplasm /cancer therapy; patient /disease registry; primary care physician

The Dayton Clinical Oncology Program (DCOP) provides access to national cooperative group clinical trials for over 1.5 million people in 11 counties in southwestern Ohio. Against this background, the DCOP has developed an eight-hospital consortium for the conduct of community based clinical trials. The eight hospital cancer registries in the consortium report over 5,000 new cancer patients per year, an increase of over 100 percent since 1980. The DCOP brings together the strength and resources of a group of multidisciplinary investigators who collaborate in the conduct of clinical trials from SWOG, NSABP, MDACC, RTOG, and the UMCCC. The investigators number 72 including 20 hematologists/oncologists, 10 radiation oncologists, 27 surgeons, and 15 colleagues in urology, pathology, gastroenterology, gynocology, and internal medicine. Over the next five years, the overall aim is to reduce cancer incidence, morbidity, and mortality by accelating the transfer of newly developed cancer prevention, early detection, treatment, patient management, rehabilitation, and continuing care technology to widespread community application. By careful design, the program will focus 50 percent of its resources on cancer control and prevention research. These complemantary objectives of both treatment and cancer prevention/control are a ready match for the patient population and fit within DCOP interest and capabilities. The immediate goals of the DCOP are to continue the strong accrual rate to treatment trials; to duplicate that effort in cancer prevention/control trials; to facilitate wider community participation, including minority groups and underserved populations; to use public education as a tool for increased awareness that will lead to increased participation; to use professional education symposia as a tool for technology transfer; to cultivate contacts with primary care physicians and other specialists who may contribute to cancer prevention/control initiatives. The DCOP will earn over 1400 credits by the year 2004. In summary, the DCOP track record demonstrates the ability to manage complex clinical research and cancer prevention/control activities while producing the highest quality data. The DCOP has the resources and well trained and experienced personnel to support both cancer treatment and prevention/control trials. The DCOP management, staffing pattern, protocol management procedures, patient/participant management approaches, data quality control mechanisims, IRB structure, and strong consortium support are in place and functioning to support current and future therapeutic and cancer prevention/control activities.

代顿临床肿瘤学项目（DCOP）为俄亥俄州西南部11个县的150多万人提供了国家合作组临床试验的机会。 在这种背景下，DCOP已经建立了一个由八家医院组成的联盟，用于开展基于社区的临床试验。 该联盟的八个医院癌症登记处报告每年有5,000多名新的癌症患者，自1980年以来增加了100%以上。DCOP汇集了一组多学科研究人员的力量和资源，他们合作开展来自SWOG，NSABP，MDACC，RTOG和UMCCC的临床试验。研究人员共有72名，其中包括20名血液科/肿瘤科医生、10名放射肿瘤科医生、27名外科医生以及15名泌尿科、病理学、胃肠科、妇科和内科同事。在未来五年内，总体目标是通过加速新开发的癌症预防、早期发现、治疗、患者管理、康复和持续护理技术向广泛的社区应用的转移，降低癌症发病率、发病率和死亡率。 通过精心设计，该计划将把50%的资源集中在癌症控制和预防研究上。 治疗和癌症预防/控制的这些互补目标是患者人群的现成匹配，并符合DCOP的兴趣和能力。 DCOP的近期目标是继续保持治疗试验的高增长率;在癌症预防/控制试验中重复这一努力;促进更广泛的社区参与，包括少数群体和得不到充分服务的人口;利用公共教育作为提高认识的工具，从而导致更多的参与;利用专业教育研讨会作为技术转让的工具;与基层保健医生和其他可能有助于癌症预防/控制措施的专家建立联系。 到2004年，DCOP将获得1400多个学分。总之，DCOP的跟踪记录证明了管理复杂的临床研究和癌症预防/控制活动的能力，同时产生最高质量的数据。 DCOP拥有资源和训练有素、经验丰富的人员来支持癌症治疗和预防/控制试验。 DCOP管理、人员配置模式、方案管理程序、患者/参与者管理方法、数据质量控制机制、IRB结构和强大的联盟支持已经到位，并正在发挥作用，以支持当前和未来的治疗和癌症预防/控制活动。